National Cancer Center, Korea
252
23
34
99
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.2%
13 terminated/withdrawn out of 252 trials
88.4%
+1.8% vs industry average
12%
31 trials in Phase 3/4
2%
2 of 99 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (252)
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
Role: collaborator
Muco-active Agent Use and Clinical Outcomes After Lung Cancer Diagnosis in Chronic Obstructive Pulmonary Disease
Role: collaborator
Prospective Study of Ultrahypofractionated Proton Beam Therapy for Localized Prostate Cancer
Role: lead
The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy
Role: lead
The DIALOGUE Study: Swiss-Korean Billateral Collaboration
Role: collaborator
PoLyglycolic Acid Felt reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial)
Role: collaborator
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Role: lead
Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
Role: collaborator
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
Role: lead
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Role: collaborator
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)
Role: lead
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
Role: collaborator
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
Role: collaborator
CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)
Role: lead
Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy
Role: lead
The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer
Role: collaborator
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
Role: lead
First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment
Role: lead
A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion
Role: lead
A Prospective Observational Study on Efficacy of TARE for Early Stage HCC
Role: collaborator